by Raynovich Rod | Sep 20, 2021 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio
Biotech and Healthcare Portfolio as of 9/17 XLV up. 17% YTD led by UNH, IBB was improving up 14.6% YTD. U.S. MedTech leads with IHI up 24% YTD. MO small cap growth stocks represented by ARKG and XBI are lagging. We won’t dig into an analysis at this moment while...
by Raynovich Rod | Aug 16, 2021 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 8/20 After a choppy week, many smaller caps turn green ! Small cap life science stocks have been in a steady sell-off but the tape looks better today. All of our recent top picks are up: CRSP, CYRX and VCYT. Indicators for momentum are also up: ARKG and XBI....
by Raynovich Rod | Jul 26, 2021 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Healthcare Stocks Are Tracking Well-Indices are at Record Highs Look to Large Cap Biopharma earnings in coming weeks. Pfizer on Wednesday. Momentum in speculative small caps are lagging so may need to wait for Q4. Macro concerns lie ahead: China, Infrastructure deal...
by Raynovich Rod | Jun 27, 2021 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks
Update-1 June 29 The Momentum indicators for biotech: ARKG was flat at $9310, XBI down 1.53% to $135.74. COVID Dx stocks were stronger ABT up 1.31% to $117.21, QDEL up 3.97% to $132.12. COVID Vaccine stocks CVAC, MRNA and NVAX were strong. Our new mid-cap picks were...
by Raynovich Rod | Jun 21, 2021 | 2021 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-1 6/22 Mixed day with a few nice moves. Vaccine stocks are up:BNTX,MRNA ,NVAX. Our Recent Mid-Cap Picks: CRISPR Therapeutics (CRSP( of 0.32%, Cryoport (CYRX) up 8.47% to $66 on Partnership deal. Veracyte (VCYT) up 1.45% to $38.56. ARKG up 0.35 to $87.68....
by Raynovich Rod | Jun 11, 2021 | 2021 Rayno Biopharmaceuticals Portfolio
6/16 At close: Benign reaction from FED meeting. Maybe investors have accepted reality that low interest rates are not going to last forever and are less ebullient. Market needs a few days to digest Chairman Powell’s remarks. Rate hikes pushed out til 2023 but...
by Raynovich Rod | Jun 9, 2021 | 2021 Rayno Biopharmaceuticals Portfolio
Update 6/14 2p -EDT The ASCO Rally tailwind looks good whether you are a trader or long term investor. As we called it on May 31 we thought the timing was right to add positions to biotech stocks. The rally is a bit more spotty now after a ~10% + move in the XBI but...
by Raynovich Rod | Jun 7, 2021 | 2021 Rayno Biopharmaceuticals Portfolio
Update-1 6/7/21 Biogen shares soar 38% to $395 handle as trading opens late in the day. Despite mixed opinions on the efficacy and cost of the drug many analysts and executives in the industry hail the FDA approval. It should boost the industry overall and provide a...
by Raynovich Rod | May 31, 2021 | 2021 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-4 6/4 11 a EDT Finally small cap biotechs catch a rally: among my holdings: CRSP, EDIT, PACB, VCYT . ARKG and IBB up. But large caps look better today.FDA authorizes Regeneron subcutaneous dosage for COVID-10 antibody therapy. Update-3 6/3 after...
